Abstract: Disclosed is an indirect enzyme-linked immunosorbent assay (ELISA) detection kit based on p30 protein and p22 protein of African swine fever (ASF) p30 and p22, belonging to the technical field of animal biological products manufacturing. The indirect ELISA detection kit includes the p30 protein with an amino acid sequence as shown in SEQ ID NO: 2 and the p22 protein with an amino acid sequence as shown in SEQ ID NO: 4.

Abstract: The present invention relates to porcine reproductive and respiratory syndrome virus (PRRSV) vaccines in a field of veterinary biological products, and more particularly to a PRRSV SX-105 strain having a deposit number of CGMCC No. 9906, and a use thereof in preparing PRRSV live vaccines. PRRSV SX-1 original strains are strongly pathogenic to swine. A PRRSV SX-105 attenuated strain shows safety and good immunogenicity on the swine. The PRRSV live vaccines, prepared from the PRRSV SX-105 strain, are safe and reliable, and able to generate strong immunity after immunization. The PRRSV live vaccines significantly decrease morbidity and mortality in inoculated swine groups, and have immunization effects reaching and slightly better than conventional commercial vaccines on the market, showing advantages to compete with the same kind of products around the world. The PRRSV live vaccines are capable of effectively preventing PRRS epidemic and transmission, and has broad application prospects.

Abstract: The present invention relates to porcine reproductive and respiratory syndrome virus (PRRSV) vaccines in a field of veterinary biological products, and more particularly to a PRRSV SX-105 strain having a deposit number of CGMCC No. 9906, and a use thereof in preparing PRRSV live vaccines. PRRSV SX-1 original strains are strongly pathogenic to swine. A PRRSV SX-105 attenuated strain shows safety and good immunogenicity on the swine. The PRRSV live vaccines, prepared from the PRRSV SX-105 strain, are safe and reliable, and able to generate strong immunity after immunization. The PRRSV live vaccines significantly decrease morbidity and mortality in inoculated swine groups, and have immunization effects reaching and slightly better than conventional commercial vaccines on the market, showing advantages to compete with the same kind of products around the world. The PRRSV live vaccines are capable of effectively preventing PRRS epidemic and transmission, and has broad application prospects.

Abstract: A combined application of Haemophilus parasuis (HPS) LC strain having a deposit number of CGMCC No. 5257 and HPS LZ-20100109 strain having a deposit number of CGMCC No. 5802 in preparing a bivalent inactivated vaccine is provided, relating to HPS disease vaccines in a field of veterinary biologics. The combined application of the HPS LC strain and the HPS LZ-20100109 strain in preparing the bivalent inactivated vaccine is safe and reliable, providing not only a homologous challenge protection against serotype 1 and serotype 5, but also certain cross protection against heterologous challenges of serotype 2, serotype 4, serotype 10, serotype 12, serotype 13, serotype 14, and serotype 15 of HPS. The combined application of the HPS LC strain and the HPS LZ-20100109 strain has an obviously increased effect. After immunizing swine, a relatively strong immunity is generated; an incidence rate and a mortality rate of inoculated swine decrease obviously.